Navigation Links
Common Heart Drug Linked to Cancer Risk in Study
Date:4/8/2013

By Steven Reinberg
HealthDay Reporter

MONDAY, April 8 (HealthDay News) -- A drug called amiodarone that's widely used to treat heartbeat irregularities might raise a patient's risk of cancer, Taiwanese researchers report.

The risk, which the researchers termed "borderline significantly increased," is more pronounced in men and patients who take high doses of the drug, according to the study, which was published online April 8 in the journal Cancer.

"When prescribing amiodarone, doctors need to keep in mind that this medication may increase cancer risk," said lead author Dr. Vincent Yi-Fong Su, from the Taipei Veterans General Hospital. "We suggest that cancer events should be routinely reported in future amiodarone trials, and further observational research is necessary."

Patients taking the drug, however, shouldn't fear they'll get cancer, one expert said.

"Amiodarone is among the most effective antiarrhythmic medications available," said Dr. Gregg Fonarow, a spokesman for the American Heart Association and professor of cardiology at the University of California, Los Angeles. "Well-controlled clinical trials have not demonstrated a significant increase in cancer with use of this medication."

The current study, called an observational study, doesn't prove that amiodarone causes cancer, only that an association was found between people taking the drug and cancer.

Many risk factors for heart disease and arrhythmia are also risk factors for cancer, Fonarow said. The findings of this study comparing those treated with amiodarone to the general population are most likely explained by selection of patients and other factors that weren't taken into account, he said.

"These findings should not be a concern to patients taking amiodarone," Fonarow said.

Amiodarone (sold as Cordarone and Pacerone) is commonly prescribed to prevent life-threatening arrhythmias, such as ventricular tachycardia or ventricular fibrillation, both of which can lead to cardiac arrest.

Ventricular tachycardia is a very rapid beating of the upper chambers of the heart. When these chambers don't beat in the correct order, the condition is called ventricular fibrillation. These problems prevent blood from being pumped properly and can cause the heart to stop beating altogether.

Amiodarone breaks down slowly, so large amounts can remain in soft tissues when the drug is taken for a long time. This might explain its association with cancer, the researchers said. Earlier studies have shown an association between amiodarone and cancer risk, but this is the largest study to date to show a link, they noted.

For the study, Su's team followed more than 6,400 patients taking amiodarone for almost three years. Among these patients, 280 developed cancer.

Men taking high doses of the drug had a 46 percent higher chance of developing cancer than those who were neither male nor taking large doses. Anyone taking high doses had nearly twice the risk of cancer compared with people taking low doses, the researchers found.

Cancers of the digestive system, lung, liver, colon, ovaries and prostate were among the cancers associated with amiodarone, the researchers said.

More information

For more information on amiodarone, visit the U.S. National Library of Medicine.

SOURCES: Vincent Yi-Fong Su, M.D., Taipei Veterans General Hospital, Taiwan; Gregg Fonarow, M.D., spokesman, American Heart Association, and professor, cardiology, University of California, Los Angeles; April 8, 2013, Cancer


'/>"/>
Copyright©2012 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Common Asphalt Sealant May Raise Cancer Risks
2. Life Extension Foundation Seeks Volunteers with Alzheimer's to Participate in a Clinical Trial Utilizing a Common Arthritis Drug
3. LSUHSC research discoveries shed light on common STI
4. Researchers are first to use common virus to fortify adult stem cells
5. Common gene variants explain 42 percent of antidepressant response
6. Paranoia Common After Mugging, Study Says
7. Hospital remains most common place of death for cancer patients in England
8. Commonly used cholesterol calculation underestimates heart disease danger for many
9. Michigan hospitals national leaders in preventing common and costly urinary tract infections
10. How common is The John Next Door?
11. Complications More Common Than Thought for Type of Hip Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Common Heart Drug Linked to Cancer Risk in Study
(Date:4/30/2017)... ... April 30, 2017 , ... TransLiquid Cartoon is a ... X. Editors can pick and choose from a variety of liquid transitions that ... shadows using simple color swabs. Utilize on-screen controls to fully manipulate transitions through ...
(Date:4/29/2017)... Aliso Viejo, CA (PRWEB) , ... April 29, 2017 , ... ... effects. Seamlessly transition from one video to the next without having to set ... bleeding, ripping, and blasting transitions to enhance your video production. , TransDark features dynamic ...
(Date:4/28/2017)... ... 2017 , ... An April 24th article on Yahoo! Beauty discusses the case of ... of a weight loss surgery. The woman, declaring “I will not hate my body anymore!” ... her dramatic weight loss. Dr. Feiz & Associates notes that, while it often refers its ...
(Date:4/28/2017)... ... April 28, 2017 , ... Beginning in 2017, Ridgecrest Herbals will ... begins with the popular ClearLungs Extra Strength formula. To ensure that the effectiveness of ... the following ways:, , Removal of the homeopathic element , ...
(Date:4/28/2017)... ... April 28, 2017 , ... ... . These lamps offer an instant energy-saving solution for F32T8 fluorescent lamps on ... or disconnect ballasts. These 50,000 hour rated lamps utilize the existing electronic ballast, ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... Calif. , April 19, 2017  IRIDEX Corporation ... will release financial results for the first quarter 2017 ... 2017.  The Company,s management team will host a corresponding ... p.m. ET. Investors interested in listening to ... 707-0665 for domestic callers or (703) 326-3030 for international ...
(Date:4/19/2017)... 19, 2017 The Global Effective Microorganisms ... 2022 report has covered and analysed the potential of Global ... market size, shares and growth factors. The report identifies and ... opportunities in the global market. ... Browse 152 Tables and Figures, 6 Major Company Profiles, ...
(Date:4/19/2017)... April 19, 2017  Novartis today announced the ... Heart, Lung, and Blood Institute (NHLBI) of the ... of patients with treatment-naïve severe aplastic anemia (SAA) ... with eltrombopag at the initiation of and concurrently ... evaluated three sequential treatment groups, or cohorts. Cohort ...
Breaking Medicine Technology: